Ajai Chari, MD

Articles by Ajai Chari, MD

Myeloma Panel Discusses 3 FDA-Approved Bispecific Agents: Talquetamab, Teclistamab, Elranatamab

Thomas Martin, MDVideo Insights | September 19, 2023

The panel discussed the FDA-approved bispecific agents for myeloma and how the options performed in clinical trials.

View More

Practical Treatment Considerations for the Use of Talquetamab in Patients with Relapsed or Refractory MM

Larysa Sanchez, MDMyeloma | May 2, 2023

This editorial outlines key practical points for the use of talquetamab in relapsed or refractory MM.

Read More

Ajai Chari, MD, Discusses the MonumenTAL-1 Study

Ajai Chari, MDVideo Insights | December 27, 2022

Ajai Chari, MD, of Mount Sinai School of Medicine, discusses results from the MonumenTAL-1 phase I/II study of talquetamab.

View More